KALV News and Press, KalVista Pharmaceuticals Inc. From 08/22/22

The shares of KalVista Pharmaceuticals, Inc. ( NASDAQ: KALV ) reached the highest level since March on Monday after Pharvaris N.V. ( PHVS ), its Dutch rival in hereditary angioedema (HAE), announced an FDA clinical hold on its lead asset, PHA121. An oral bradykinin B2-...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the 1 st Annual H.C. Wainwright Hereditary Angioe...

KalVista Pharmaceticals press release ( NASDAQ: KALV ): Q4 GAAP EPS of -$0.98 beats by $0.11 . Cash, cash equivalents and marketable securities were $166.2M on April 30, 2022, compared to $248.9M on April 30, 2021. The decrease in the net cash position over the fiscal ...

– Sebetralstat data examines efficacy by attack location and population PK comparisons – – Preclinical data for oral Factor XIIa inhibitor shows durable suppression of kallikrein-kinin system - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a cli...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2022 European Academy of Allergy a...

– First preclinical data presented for structurally diverse oral Factor XIIa inhibitors - – Additional Sebetralstat data also presented - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, de...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the 13 th Annual Jefferies Global Healthcare Conf...

– “Sebetralstat” Approved by WHO and USAN – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today anno...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the 21 st Annual Needham Virtual Healthcare Confe...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication of new data in Clinical & Experimental Allergy charact...